The dark side of Europe's streets has been cast into sharper relief in recent years, as increasingly potent synthetic opioids fuel a rise in drug-related harm and fatalities. Now, in a major bid to stem this tide, the UK government and the European Union Drugs Agency (EUDA) have formally signed a Working Arrangement aimed at bolstering their collective ability to safeguard public health.
This landmark agreement establishes a framework for the reciprocal exchange of critical information on newly detected substances, emerging drug threats, and high-risk drugs currently in circulation. The data shared will enable both the UK and the EU to identify potential risks earlier and formulate more effective responses to the evolving landscape of drug-related harms.
The need for such collaboration is evident from the statistics: potent synthetic opioids have been driving a surge in drug-related incidents, with devastating consequences. Improved information exchange, expertise sharing, and alerts on emerging threats are expected to significantly strengthen the collective capacity to respond and reduce harm across the continent.
Beyond immediate threat identification, the arrangement also fosters broader cooperation in areas such as drug prevention, treatment, social reintegration, and harm reduction. It aims to enhance a shared understanding of drug supply chains and trafficking routes across the UK and Europe, equipping both parties to address dynamic drug markets more effectively.
This agreement fulfils a commitment made at the 2025 UK-EU Summit, where both sides agreed to establish a working arrangement for reciprocal information exchange on drug risks and threats. The pact forms part of wider UK-EU cooperation in areas of shared interest, underscoring their continued commitment to collaborative solutions for cross-border issues.